950577-02-3

Basic information

• Product Name: 6-BROMO-7-FLUOROQUINAZOLIN-4-OL
• Synonyms: 6-BROMO-7-FLUOROQUINAZOLIN-4-OL;6-Bromo-7-fluoro-4(3H)-quinazolinone;6-Bromo-7-fluoro-1H-quinazolin-4-one
• CAS NO: 950577-02-3
• Molecular Formula: C8H4BrFN2O
• Molecular Weight: 243.03
• Mol File: 950577-02-3.mol

Chemical Properties

• Boiling Point: 358.3±52.0 °C(Predicted)
• Appearance: /
• Density: 1.92±0.1 g/cm3(Predicted)
• PKA: -0.63±0.20(Predicted)
• CAS DataBase Reference: 6-BROMO-7-FLUOROQUINAZOLIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-7-FLUOROQUINAZOLIN-4-OL(950577-02-3)
• EPA Substance Registry System: 6-BROMO-7-FLUOROQUINAZOLIN-4-OL(950577-02-3)

Safety Data

• Hazardous Substances Data: 950577-02-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-7-fluoroquinazolin-4-ol is used as a potential pharmaceutical candidate for the development of new drugs. Its unique structure and chemical properties make it a promising compound for the treatment of various diseases and conditions. The bromine and fluorine substituents in its structure may enhance its pharmacological properties, such as its ability to target specific biological pathways or receptors.
Used in Chemical Synthesis:
6-Bromo-7-fluoroquinazolin-4-ol is used as a building block in the synthesis of more complex molecules. Its quinazoline ring and halogen substituents can be further modified or functionalized to create a variety of new compounds with different properties and applications. This makes it a valuable intermediate in the development of novel pharmaceuticals, agrochemicals, or other specialty chemicals.
Further research and testing would be required to fully understand the potential uses and effects of 6-bromo-7-fluoroquinazolin-4-ol, as well as to optimize its synthesis and application in various industries.

Upstream product

• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 143945-65-7 2-amino-4-fluoro-5-bromobenzoic acid 
• 3473-63-0 formamidine acetic acid 

Downstream Products

• 850140-72-6 afatinib 
• 1256955-27-7 6-bromo-4-chloro-7-methoxyquinazoline 

Relevant articles and documents

An alternative synthesis of the non-small cell lung carcinoma drug afatinib

Afatinib (BIBW2992) is the anticancer drug developed by Boehringer Ingelheim. This work is reporting the synthesis of the afatinib using a new route by Ullmann-Goldberg reaction from corresponding 4-anilinoquinazoline iodide as the last step in the synthesis. This route was not described previously and it could be used for synthesis of afatinib analogues.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof

Substituted 4-amino-quinazoline compounds corresponding to formula I methods for their production, pharmaceutical compositions containing these compounds as active agents, and the uses thereof for treating or inhibiting disorders or disease states.